ECSP13012476A - Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas - Google Patents

Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas

Info

Publication number
ECSP13012476A
ECSP13012476A ECSP13012476A ECSP13012476A EC SP13012476 A ECSP13012476 A EC SP13012476A EC SP13012476 A ECSP13012476 A EC SP13012476A EC SP13012476 A ECSP13012476 A EC SP13012476A
Authority
EC
Ecuador
Prior art keywords
vzv
inactivated
virus
zacster
varicela
Prior art date
Application number
Other languages
English (en)
Inventor
Mary K Yagodich
David L Krah
Jill Dehaven
Jennifer A Kriss
Colleen M Barr
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP13012476A publication Critical patent/ECSP13012476A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25Varicella-zoster virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

RESUMEN DE LA DESCRIPCIÓN La invención proporciona un virus varicela zóster (VVZ) inactivado, y composiciones y vacunas que comprenden dicho VVZ inactivado, donde la infectividad del VVZ es indetectable y donde el VVZ inactivado induce una respuesta inmune contra VVZ cuando se administra a un paciente. En realizaciones de las composiciones descritas en el presente documento, el VVZ se inactiva con radiación gamma. La invención también proporciona un método para preparar una vacuna de VVZ inactivado, comprendiendo el método someter a irradiación gamma una muestra que comprende VVZ usando de aproximadamente 5 kGy a aproximadamente 50 kGy de irradiación gama. También se proporciona por la invención del presente documento un método de tratamiento o de inmunización contra HZ u otra enfermedad asociada con la reactivación de VVZ, comprendiendo el método administrar a un sujeto una vacuna o composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un VVZ inactivado y un vehículo farmacéuticamente aceptable, donde el VVZ se inactiva por irradiación gamma.
ECSP13012476 2010-08-05 2013-03-04 Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas ECSP13012476A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37103810P 2010-08-05 2010-08-05

Publications (1)

Publication Number Publication Date
ECSP13012476A true ECSP13012476A (es) 2013-04-30

Family

ID=45556327

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012476 ECSP13012476A (es) 2010-08-05 2013-03-04 Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas

Country Status (23)

Country Link
US (3) US20120034267A1 (es)
EP (2) EP2600893A4 (es)
JP (2) JP2013535488A (es)
KR (3) KR20130036062A (es)
CN (1) CN103167880B (es)
AR (1) AR082577A1 (es)
AU (1) AU2011285749B2 (es)
BR (1) BR112013001946A2 (es)
CA (1) CA2806454A1 (es)
CL (2) CL2013000360A1 (es)
CO (1) CO6731067A2 (es)
EC (1) ECSP13012476A (es)
MX (1) MX343600B (es)
MY (1) MY158419A (es)
NZ (1) NZ606549A (es)
PE (1) PE20131336A1 (es)
PH (1) PH12013500133A1 (es)
RU (1) RU2633058C2 (es)
SG (1) SG187222A1 (es)
TW (1) TW201208698A (es)
UA (1) UA112970C2 (es)
WO (1) WO2012018973A1 (es)
ZA (1) ZA201300622B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034807A2 (en) 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
RU2651040C2 (ru) * 2016-08-08 2018-04-18 Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Вакцина оспенная инактивированная эмбриональная сухая таблетированная для орального применения "ТЭОВин" и способ ее получения
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法
CN109453371A (zh) * 2018-11-23 2019-03-12 中国兽医药品监察所 一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法
RU2700410C1 (ru) * 2019-05-20 2019-09-17 Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН) Метод иммуноокрашивания биологического материала для конфокальной микроскопии
CA3158539A1 (en) 2019-12-16 2021-06-24 Johanna Jacoba Elisabeth Bijlsma Inactivated piscine orthoreovirus vaccine
WO2024191324A1 (ru) * 2023-03-13 2024-09-19 Олег Александрович ШИЛОВ Способ получения препарата вакцины из цельных вирусов или бактерий

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (es) 1974-03-12 1978-11-01
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
WO1994002596A1 (en) * 1992-07-17 1994-02-03 Merck & Co., Inc. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001087357A2 (en) * 2000-05-17 2001-11-22 The American National Red Cross Gamma irradiation of protein-based pharmaceutical products
US6946098B2 (en) * 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1721981A4 (en) * 2004-03-05 2007-03-14 Univ Osaka Res Found RECOMBINANT VARICELLA ZOSTER VIRUS
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа

Also Published As

Publication number Publication date
MX2013001434A (es) 2013-03-12
JP2016053032A (ja) 2016-04-14
EP2600893A1 (en) 2013-06-12
AR082577A1 (es) 2012-12-19
RU2013109417A (ru) 2014-09-10
ZA201300622B (en) 2013-09-25
UA112970C2 (uk) 2016-11-25
PH12013500133A1 (en) 2013-03-11
US20180318412A1 (en) 2018-11-08
CN103167880B (zh) 2016-05-18
PE20131336A1 (es) 2013-11-21
WO2012018973A1 (en) 2012-02-09
CL2016003181A1 (es) 2017-06-02
SG187222A1 (en) 2013-03-28
MX343600B (es) 2016-11-10
BR112013001946A2 (pt) 2016-05-24
US20150209424A1 (en) 2015-07-30
AU2011285749A1 (en) 2013-01-31
RU2633058C2 (ru) 2017-10-11
AU2011285749B2 (en) 2014-07-31
MY158419A (en) 2016-10-14
EP3363894A1 (en) 2018-08-22
US20120034267A1 (en) 2012-02-09
KR20130036062A (ko) 2013-04-09
NZ606549A (en) 2014-12-24
JP2013535488A (ja) 2013-09-12
CL2013000360A1 (es) 2014-03-28
TW201208698A (en) 2012-03-01
EP2600893A4 (en) 2014-01-22
CN103167880A (zh) 2013-06-19
KR20160060790A (ko) 2016-05-30
CO6731067A2 (es) 2013-08-15
CA2806454A1 (en) 2012-02-09
KR20160018828A (ko) 2016-02-17

Similar Documents

Publication Publication Date Title
ECSP13012476A (es) Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas
MX374287B (es) Formulacion que contiene virus y uso de la misma.
Koraka et al. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
Wijesinghe et al. Current vaccine approaches and emerging strategies against herpes simplex virus (HSV)
PE20151588A1 (es) Vacuna contra el virus del dengue
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
KR20140033171A (ko) 비활성화된 뎅기 바이러스 백신
TR201908199T4 (tr) HPV'ye karşı aşılar.
Del Giudice et al. Vaccines for the elderly
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
BR112014001798A2 (pt) compostos de tetraciclina 9-aminometila substituídos
Garçon et al. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt
JP6985384B2 (ja) 弱毒変異型ジカウイルスを含むワクチン組成物
JP2015531389A5 (es)
PE20110327A1 (es) Vacuna contra el virus de papiloma humano
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
Lei et al. A vaccine delivery system promotes strong immune responses against SARS‐CoV‐2 variants
BR112013006515B1 (pt) vacina de combinação, e, método para a fabricação de uma vacina de combinação
Verma et al. Intra-dermal administration of rabies vaccines in developing countries: at an affordable cost
JP7046848B2 (ja) 弱毒化突然変異体ジカウイルスをコードするゲノム配列
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
WO2015034807A3 (en) Methods of immunization with varicella zoster virus antigen
Lee et al. Nanomedicine in the development of vaccines against Herpesviridae: a narrative review